Skip to main content
Premium Trial:

Request an Annual Quote

Merck, LabCorp in PGx Licensing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Merck said after the close the market yesterday that it has granted Laboratory Corporation of America a non-exclusive license to commercialize a genetic test to help predict patient response to peginterferon alpha-based therapy for hepatitis C virus.

LabCorp has developed a test to identify the presence of IL-28B, a genetic mutation that has been associated with a successful response to peginterferon alpha-based therapy, which Merck said is the current standard of care for hepatitis C virus. Merck identified that association through a genome-wide study sponsored by the firm of nearly 1,700 patients with HCV genotype 1.

Under the agreement, LabCorp will pay a Merck affiliate a one-time payment and royalties for tests covered under the pact. In exchange, LabCorp receives a license to the Merck affiliate's patent rights covering the detection and use of the IL-28B polymorphism.

Further terms of the deal were not disclosed.

Merck noted that it intends to provide a limited number of non-exclusive licenses for the polymorphism to established diagnostic companies.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.